Scarica l'app Stockscreener
42.90
2.23%
-0.98
Dopo l'orario di chiusura:
42.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$43.88
Aprire:
$44.17
Volume 24 ore:
325.63K
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.53B
Reddito:
$154.15M
Utile/perdita netta:
$-33.58M
Rapporto P/E:
-76.61
EPS:
-0.56
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+9.97%
1M Prestazione:
-24.71%
6M Prestazione:
+149.13%
1 anno Prestazione:
+366.81%
Intervallo 1D:
$42.73
$44.45
Intervallo di 1 settimana:
$37.00
$44.45
Portata 52W:
$8.7202
$59.23
Harrow Inc Stock (HROW) Company Profile
Nome
Harrow Inc
Settore
Telefono
615.733.4731
Indirizzo
102 WOODMONT BLVD, NASHVILLE, CA
Confronta HROW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| HROW | 42.90 | 1.53B | 154.15M | -33.58M | -20.74M | -0.56 |
| ZTS | 176.96 | 79.84B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.65 | 43.63B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.38 | 42.42B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.37 | 15.96B | 15.05B | -883.30M | 1.89B | 1.53 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-09-08 | Ripresa | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-09-24 | Iniziato | Aegis Capital | Buy |
| 2021-07-02 | Iniziato | Ladenburg Thalmann | Buy |
Harrow Inc Borsa (HROW) Ultime notizie
Connor Clark & Lunn Investment Management Ltd. Invests $5.86 Million in Harrow, Inc. (NASDAQ:HROW) - MarketBeat
Harrow subsidiary wins $34.9 million in trademark case By Investing.com - Investing.com Canada
Harrow subsidiary wins $34.9 million in trademark case - Investing.com
Harrow Wins $34.9M Verdict in Major Trademark Infringement Case Against OSRX | HROW Stock News - StockTitan
HROW (Harrow) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Capex-to-Operating-Cash-Flow : 0.20 (As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Cash Flow from Investing : $4.2 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Change In Receivables : $-35.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Change In Inventory : $-1.2 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Total Inventories : $10.2 Mil (As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Cash Flow for Dividends : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Long-Term Debt & Capital Lease Obligation : $195.6 Mil (As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Cash Flow from Financing : $-1.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Cash Flow from Operations : $4.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) Operating Cash Flow per Share : $0.12 (TTM As of Sep. 2024) - GuruFocus.com
HROW (Harrow) PE Ratio without NRI : At Loss (As of Nov. 20, 2024) - GuruFocus.com
HROW (Harrow) Total Assets : $351.5 Mil (As of Sep. 2024) - GuruFocus.com
Former Harrow unit Melt announces results for MELT-300 to sedate for surgery - TipRanks
First Turn Management LLC Purchases New Position in Harrow, Inc. (NASDAQ:HROW) - MarketBeat
28,177 Shares in Harrow, Inc. (NASDAQ:HROW) Purchased by Oppenheimer & Co. Inc. - MarketBeat
Harrow, Inc. (NASDAQ:HROW) Stock Position Lessened by Royce & Associates LP - MarketBeat
Harrow Stock: Spotlight On IHEEZO (NASDAQ:HROW) - Seeking Alpha
Harrow (NASDAQ:HROW) Shares Down 7.3%Here's Why - MarketBeat
Harrow Announces Participation in Upcoming Investor Conferences - BioSpace
Harrow Health, Inc. (NASDAQ:HROW) Q3 2024 Earnings Call Transcript - Insider Monkey
Harrow to Present at Major Healthcare Conferences, Including Piper Sandler's Annual Event | HROW Stock News - StockTitan
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... By GuruFocus - Investing.com Canada
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... - Yahoo Finance
Harrow Inc Com (HROW) Quarterly 10-Q Report - Quartz
Harrow Grows Revenue 44 Percent in 2024 Third Quarter, Confirms Full-Year Guidance - Vision Monday
Harrow Inc. Reports Strong Q3 2024 Growth - TipRanks
Harrow (NASDAQ:HROW) Shares Gap DownWhat's Next? - MarketBeat
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q3 2024 Harrow Inc Earnings Call Transcript - GuruFocus.com
Harrow Inc (HROW) Q3 2024 Earnings: Revenue at $49.3M, Misses Es - GuruFocus.com
Los Angeles Capital Management LLC Sells 38,168 Shares of Harrow, Inc. (NASDAQ:HROW) - MarketBeat
Harrow: Q3 Earnings Snapshot - New Haven Register
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Harrow stock plunges 20% on weaker-than-expected Q3 earnings - MSN
Harrow stock plunges 20% on weaker-than-expected Q3 earnings (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
HROWHarrow, Inc. Latest Stock News & Market Updates - StockTitan
Harrow Q3 Revenue Surges 44% to $49.3M as VEVYE Prescriptions Jump 55% | HROW Stock News - StockTitan
Harrow Inc (HROW) Shares Up 6.99% on Nov 13 - GuruFocus.com
Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Harrow Partners with GoodRx, Cuts Prices on Key Eye Drug Portfolio | HROW Stock News - StockTitan
Harrow secures Medicare coverage for dry eye treatment VEVYE By Investing.com - Investing.com Canada
Harrow Inc (HROW) Stock Price Down 3.18% on Nov 12 - GuruFocus.com
Earnings Outlook For Harrow - Benzinga
Harrow secures Medicare coverage for dry eye treatment VEVYE - Investing.com India
Harrow Inc Azioni (HROW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Harrow Inc Azioni (HROW) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Apr 25 '24 |
Buy |
9.97 |
20,000 |
199,400 |
3,815,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 23 '24 |
Buy |
10.29 |
11,715 |
120,547 |
3,786,715 |
| Opaleye Management Inc. | 10% Owner |
Apr 24 '24 |
Buy |
10.15 |
8,285 |
84,093 |
3,795,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 19 '24 |
Buy |
10.56 |
29,400 |
310,390 |
3,775,000 |
| Opaleye Management Inc. | 10% Owner |
Mar 28 '24 |
Buy |
12.82 |
50,000 |
641,000 |
3,745,600 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Mar 22 '24 |
Buy |
11.59 |
9,000 |
104,310 |
2,137,525 |
| Opaleye Management Inc. | 10% Owner |
Mar 20 '24 |
Buy |
9.65 |
50,600 |
488,290 |
3,695,600 |
| SAHAREK JOHN P. | CEO of ImprimisRx |
Mar 01 '24 |
Option Exercise |
8.75 |
5,000 |
43,750 |
254,803 |
| SAHAREK JOHN P. | CEO of ImprimisRx |
Feb 20 '24 |
Option Exercise |
10.67 |
30,000 |
320,100 |
262,419 |
| BOLL ANDREW R. | CHIEF FINANCIAL OFFICER |
Feb 20 '24 |
Option Exercise |
10.67 |
45,000 |
480,150 |
586,569 |
3.66%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):